Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
20.65
+0.31 (1.52%)
Dec 20, 2024, 4:00 PM EST - Market closed
Tourmaline Bio Employees
Tourmaline Bio had 44 employees as of December 31, 2023.
Employees
44
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,451,750
Market Cap
529.52M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Pacific Biosciences of California | 796 |
Talkspace | 472 |
Phathom Pharmaceuticals | 452 |
ORIC Pharmaceuticals | 100 |
CorMedix | 83 |
Terns Pharmaceuticals | 66 |
Astria Therapeutics | 59 |
Mind Medicine (MindMed) | 57 |
TRML News
- 11 days ago - Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - GlobeNewsWire
- 5 weeks ago - Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - GlobeNewsWire
- 6 weeks ago - Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Tourmaline Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - GlobeNewsWire
- 2 months ago - Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting - Seeking Alpha
- 2 months ago - Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - GlobeNewsWire
- 2 months ago - Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board - GlobeNewsWire